IGFBPL1 anticorps (AA 201-278) (AbBy Fluor® 488)
-
- Antigène Tous les produits IGFBPL1
- IGFBPL1 (Insulin-Like Growth Factor Binding Protein-Like 1 (IGFBPL1))
-
Épitope
- AA 201-278
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp IGFBPL1 est conjugé à/à la AbBy Fluor® 488
-
Application
- Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc))
- Homologie
- Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Horse
- Purification
- Purified by Protein A.
- Immunogène
- KLH conjugated synthetic peptide derived from human IGFBPL1
- Isotype
- IgG
-
-
- Indications d'application
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Agent conservateur
- ProClin
- Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Date de péremption
- 12 months
-
- Antigène
- IGFBPL1 (Insulin-Like Growth Factor Binding Protein-Like 1 (IGFBPL1))
- Autre désignation
- Igfbpl1 (IGFBPL1 Produits)
- Synonymes
- anticorps IGFBP-RP4, anticorps IGFBPRP4, anticorps bA113O24.1, anticorps 2810011G06Rik, anticorps 2810453O06Rik, anticorps IGFBPL, anticorps insulin like growth factor binding protein like 1, anticorps insulin-like growth factor binding protein-like 1, anticorps IGFBPL1, anticorps Igfbpl1
- Sujet
-
Synonyms: bA113O24.1, IGFBP-related protein 10, IGFBP-RP4, IGFBPRP4, insulin-like growth factor binding protein related protein 4, insulin-like growth factor-binding protein-like 1, IBPL1_HUMAN, insulin-like growth factor-binding-related protein 4.
Background: IGFBPL1 is a secreted IGF (Insulin-like growth factor) binding protein that is known to contain an Ig-like C2-type (immunoglobulin-like) domain, an IGFBP N-terminal domain and a Kazal-like domain. IGF-binding proteins characteristically act to extend the half-life of IGFs and may influence the growth promoting effects of the IGFs. The interaction of IGFBPs with IGFs can affect cell surface receptors, specifically, IGFBPs may enhance or decrease a cells insulin sensitivity. IGFBPL1 has been found to be down-regulated in multiple tumors and thus may be a likely tumor suppressor candidate. Highly expressed in both brain and testis, IGFBPL1 is found at lower levels in the prostate, bladder and lung.
-